研究单位：[1]Beijing InnoCare Pharma Tech Co.,Ltd.[2]The first Affiliated Hospital of Kunming Medical University Kunming,Yunnan,China[3]The First Affiliated Hospital of Bengbu Medical College Bengbu,Anhui,China[4]Anhui Provincial Cancer Hospital Hefei,Anhui,China[5]The Fifth Medical Center of PLA General Hospital Beijing,Beijing,China[6]The First Affiliated Hospital of Congqing Medical University Chongqing,Chongqing,China,400000[7]The Second Affiliated Hospital of Army Medical University Chongqing,Chongqing,China[8]The First Affiliated Hospital of Xiamen University Xiamen,Fujian,China[9]Lanzhou University Second Hospital Lanzhou,Gansu,China[10]Dongguan People's Hospital Dongguan,Guangdong,China,523058
研究目的：
This is a randomized, multicenter, open-label, Phase 3 study to evaluate the efficacy and safety of ICP-022 versus Chlorambucil plus Rituximab in subjects with Previously Untreated Chronic Lymphocytic Leukemia.
